{"id":5639,"date":"2023-11-21T13:58:05","date_gmt":"2023-11-21T13:58:05","guid":{"rendered":"https:\/\/aceoncology.org\/?post_type=ace_education&#038;p=5639"},"modified":"2023-12-18T11:24:27","modified_gmt":"2023-12-18T11:24:27","slug":"expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc","status":"publish","type":"ace_education","link":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/","title":{"rendered":"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC)"},"content":{"rendered":"\n<p>About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmette-Gu\u00e9rin (BCG) or intravesical chemotherapy (mitomycin C, epirubicin, or doxorubicin). The decision to instill BCG and\/or chemotherapy is based on the risk of cancer progression or recurrence.<\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>For practicing oncologists, it is crucial to address Frequently Asked Questions (FAQs) regarding NMIBC such as how to define individual risk groups and treatment recommendations for each group, how to identify BCG refractoriness and relapse in clinical practice, and how to manage patients who are BCG refractory.<\/p>\n\n\n\n<div style=\"height:18px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Let&#8217;s watch the recorded video on &#8216;Frequently Asked Questions (FAQs) for NMIBC&#8217; to gain comprehensive insights from leading experts \u2013 Dr. Francisco X. Real from National Cancer Research Center of Spain and Dr. F\u00e9lix Guerrero Ramos from Hospital Universitario 12 de Octubre in Madrid, Spain.<\/p>\n\n\n\n<div style=\"height:17px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This program is available with subtitles in the following languages:<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/05\/Screenshot-2023-05-10-144115.png\" alt=\"This image has an empty alt attribute; its file name is Screenshot-2023-05-10-144115.png\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>About 70% to 80% of bladder cancers present as non-musc [&hellip;]<\/p>\n","protected":false},"author":719,"featured_media":5288,"template":"","ace_education_category":[35],"ace_education_tag":[],"class_list":["post-5639","ace_education","type-ace_education","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC) - ACE Oncology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC) - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"About 70% to 80% of bladder cancers present as non-musc [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-18T11:24:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"721\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/\",\"name\":\"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC) - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"datePublished\":\"2023-11-21T13:58:05+00:00\",\"dateModified\":\"2023-12-18T11:24:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"width\":721,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5728\u7ebf\u6559\u80b2\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/education\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC) - ACE Oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/","og_locale":"zh_CN","og_type":"article","og_title":"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC) - ACE Oncology","og_description":"About 70% to 80% of bladder cancers present as non-musc [&hellip;]","og_url":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/","og_site_name":"ACE Oncology","article_modified_time":"2023-12-18T11:24:27+00:00","og_image":[{"width":721,"height":450,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ace_oncology","twitter_misc":{"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/","url":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/","name":"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC) - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","datePublished":"2023-11-21T13:58:05+00:00","dateModified":"2023-12-18T11:24:27+00:00","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","width":721,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-1-frequently-asked-questions-faqs-for-non-muscle-invasive-bladder-cancer-nmibc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u5728\u7ebf\u6559\u80b2","item":"https:\/\/aceoncology.org\/zh-hans\/education\/"},{"@type":"ListItem","position":3,"name":"Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC)"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education\/5639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/ace_education"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/5288"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=5639"}],"wp:term":[{"taxonomy":"ace_education_category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_category?post=5639"},{"taxonomy":"ace_education_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_tag?post=5639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}